Results 81 to 90 of about 19,011 (195)

Liver Steatosis in Induced Hepatocytes From Carriers of Spinal Muscular Atrophy

Muscle &Nerve, Volume 73, Issue 4, Page 675-682, April 2026.
ABSTRACT Introduction/Aims Although classically characterized as a motor neuron disease, spinal muscular atrophy (SMA) is increasingly recognized as a multisystem disorder. We previously showed hepatocyte‐intrinsic steatosis in SMA, raising the question of whether SMA carriers, who are typically asymptomatic, may also exhibit subclinical hepatic ...
Lingyu Sun, Damien Meng Kiat Leow, Loo Chien Wang, Michelle Yating Eio, Hiromi W. L. Koh, Zi Jian Khong, Gunaseelan Narayanan, Aloysius Kai Soon Teo, Richard Giadone, Radoslaw M. Sobota, Shi Yan Ng, Adrian Kee Keong Teo, Wei Yi Ong, Lee L. Rubin, Basil T. Darras, Crystal J. J. Yeo   +15 more
wiley   +1 more source

Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice

Drug Design, Development and Therapy, 2015
Michael R Preusch,1,2 Nicholas Ieronimakis,1 Errol S Wijelath,3 Sara Cabbage,1 Jerry Ricks,1 Florian Bea,2 Morayma Reyes,1 Joanne van Ryn,4 Michael E Rosenfeld1,5 1Department of Pathology, University of Washington, Seattle, WA, USA; 2Department of ...
Preusch MR, Ieronimakis N, Wijelath ES, Cabbage S, Ricks J, Bea F, Reyes M, van Ryn J, Rosenfeld ME   +8 more
doaj  

Bioactive recombinant human oncostatin M for NMR-based screening in drug discovery

Scientific Reports, 2021
Oncostatin M (OSM) is a pleiotropic, interleukin-6 family inflammatory cytokine that plays an important role in inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis, and cancer progression and metastasis.
Olga A. Mass, Joseph Tuccinardi, Luke Woodbury, Cody L. Wolf, Bri Grantham, Kelsey Holdaway, Xinzhu Pu, Matthew D. King, Don L. Warner, Cheryl L. Jorcyk, Lisa R. Warner   +10 more
doaj   +1 more source

Oncostatin M-induced genes in human astrocytomas

International Journal of Oncology, 2007
Oncostatin M (OSM) is a member of the interleukin-6 (IL-6) cytokine family and known to be induced in the nervous system as a result of cell stress. OSM is expressed in most human brain tumors, but the effects on tumor cells are unclear. The cytokine is known to activate the JAK/STAT signaling pathway by binding to its receptors gp130/OSMbeta or gp130 ...
Annika, Krona, Pierre, Aman, Charlotte, Orndal, Agnetha, Josefsson   +3 more
openaire   +3 more sources

Multiscale Hybrid Surface Topographies Orchestrate Immune Regulation, Antibacterial Defense, and Tissue Regeneration

Advanced Healthcare Materials, Volume 15, Issue 11, 20 March 2026.
Hybrid wrinkled topographies coordinate immune, tissue, and bacterial interactions. The surfaces promote osteointegration, tune macrophage polarization, and inhibit biofilm formation, highlighting a multifunctional strategy for next‐generation implant design.
Mohammad Asadi Tokmedash, Jacob Robins, J. Scott VanEpps, Minji Kim, Jouha Min   +4 more
wiley   +1 more source

The Nuclear Protein HOXB13 Enhances Methylmercury Toxicity by Inducing Oncostatin M and Promoting Its Binding to TNFR3 in Cultured Cells

Cells, 2019
Homeobox protein B13 (HOXB13), a transcription factor, is related to methylmercury toxicity; however, the downstream factors involved in enhancing methylmercury toxicity remain unknown.
Takashi Toyama, Sidi Xu, Ryo Nakano, Takashi Hasegawa, Naoki Endo, Tsutomu Takahashi, Jin-Yong Lee, Akira Naganuma, Gi-Wook Hwang   +8 more
doaj   +1 more source

Oncostatin M enhances the antiviral effects of type I interferon and activates immunostimulatory functions in liver epithelial cells [PDF]

, 2009
Oncostatin M (OSM) is released together with type I interferon (IFN) by activated dendritic cells, suggesting a concerted action of these cytokines in the biological response against infection.
Larrea, E. (Esther), Aldabe, R. (Rafael), Gonzalez, I. (Iranzu), Segura, V. (Víctor), Sarobe, P. (Pablo), Echeverria, I. (Itziar), Prieto, J. (Jesús)   +6 more
core   +1 more source

Impact of Obesity on the Structured Histopathology of Chronic Rhinosinusitis Patients

The Laryngoscope, Volume 136, Issue 3, Page 1150-1157, March 2026.
ABSTRACT Objectives Obesity is an established risk factor for asthma, which shares common inflammatory pathways with chronic rhinosinusitis (CRS). However, the link between obesity and CRS remains poorly understood. By identifying trends in the structured histopathology (SHP) of obese patients with CRS, we aim to better understand how changes in the ...
Daniel X. Ma, Sushanth Neerumalla, Ali Baird, Russell A. Whitehead, Peter Filip, Bobby A. Tajudeen, Pete S. Batra, Peter Papagiannopoulos   +7 more
wiley   +1 more source

Oncostatin m is produced in adipose tissue and is regulated in conditions of obesity and type 2 diabetes [PDF]

, 2013
CONTEXT: Adipose tissue is a highly active endocrine organ that secretes many factors that affect other tissues and whole-body metabolism. Adipocytes are responsive to several glycoprotein 130 (gp130) cytokines, some of which have been targeted as ...
Albasanz-Puig, Alessi, Anthony W. Ferrante, Balhoff, Blüher, Blüher, Brown, Carrie M. Elks, Celik, Crowe, David Sanchez-Infantes, Demyanets, Di Gregorio, Eric Ravussin, Ettinger, Fasnacht, Febbraio, Fried, Ghosh, Gloaguen, Hansen, Heinrich, Henkel, Hui, Jacqueline M. Stephens, Jeffrey M. Gimble, Kamiya, Kern, Komori, Lambert, Lehr, López, Miyaoka, Mohamed-Ali, Mosley, Nakamura, Natal, Okaya, Ouchi, Pradeep, Rega, Robert V. Considine, Ron F. Morrison, Rose, Rose, Rotter, Sleeman, Slevin, Song, Stephens, Suda, Tamura, Tenney, Ursula A. White, Virtue, Wahl, Wallace, Wallenius, Weisberg, White, White, Zarling, Zvonic, Zvonic   +63 more
core   +2 more sources

Population Pharmacokinetic Analysis of Vixarelimab in Healthy Volunteers and Patients With Chronic Pruritic Conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 3, March 2026.
ABSTRACT Vixarelimab is a first‐in‐class fully human monoclonal antibody targeting oncostatin M (OSM) receptor beta (OSMRβ). It has been evaluated in Phase 1 and 2 studies in healthy volunteers and patients with chronic pruritic conditions and demonstrated anti‐pruritic efficacy in a Phase 2 study in prurigo nodularis, but detailed pharmacokinetic ...
Fei Tang, Steve Dang, Audrey Arjomandi, Lin Pan, Joy Hsu, Smita Kshirsagar, Nastya Kassir   +6 more
wiley   +1 more source